Elevated glutathione as a therapeutic strategy in Alzheimer's disease

Drug Development Research

Volumn 56, Issue 3, 2002, Pages 428-437

  Butterfield, D Allan ^a   Pocernich, Chava B ^a   Drake, Jennifer ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's disease; Glutathione; Lipid peroxidation products; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; CYSTEINYLGLYCINE; GAMMA GLUTAMYLCYSTEINE; GLUTAMINE; GLUTATHIONE; GLUTATHIONE ETHYL ESTER; REACTIVE OXYGEN METABOLITE; THIAZOLIDINE 2 OXOTHIAZOLIDINE 4 CARBOXYLATE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; LIPID PEROXIDATION; NERVE DEGENERATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN BINDING; REVIEW; SYNAPTIC TRANSMISSION; WHEY;

EID: 0036660272     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10095     Document Type: Review

References (121)

1. Adair JC, Knoefel JE, Morgan N. 2001. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 57:1515-1517.
2. Anderson ME, Luo J. 1998. Glutathione therapy: from prodrugs to genes. Semin Liver Dis 18:415-424.
3. Anderson ME, Meister A. 1983. Transport and direct utilization of gamma-glutamylcyst(e)ine for glutathione synthesis. Proc Natl Acad Sci USA 80:707-711.
4. Anderson ME, Meister A. 1989. Glutathione monoesters. Anal Biochem 183:16-20.
5. Anderson ME, Powrie F, Puri RN, Meister A. 1985. Glutathione monoethyl ester: preparation, uptake by tissues, and conversion to glutathione. Arch Biochem Biophys 239:538-548.
6. Bains JS, Shaw CA. 1997. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Rev 25:335-358.
7. Barditch-Crovo P, Noe D, Skowron G. 1998. A phase I/II evaluation of oral L-2-oxothiazolidine-4-carboxylic acid in asymptomatic patients infected with human immunodeficiency virus. J Clin Pharmacol 38:357-363.
8. Barger SW, Basile AS. 2001. Activation of microglia by secreted amyloid precursor protein evokes release of glutamate by cystine exchange and attenuates synaptic function. J Neurochem 76:846-854.
9. Barker JE, Bolanos JP, Land JM, Clark JB, Heales SJ. 1996. Glutathione protects astrocytes from peroxynitrite-mediated mitochondrial damage: implications for neuronal/astrocytic trafficking and neurodegeneration. Dev Neurosci 18:391-396.
10. Benzi G, Moretti A. 1997. Age and peroxidative stress-related modifications of the cerebral enzymatic activities linked to mitochondria and the glutathione system. Free Radic Biol Med 19:77-101.
11. Bernard C, Wheeler A, Arons M. 1997. A trail of antioxidants N-acetylcysteine and procysteine in ARDS. The autioxidant in ARDS Study Group. Chest 112:164-172.
12. Bernoud-Hubac N, Davies SS, Boutaud O, Montine TJ, Roberts LJ 2nd. 2001. Formation of highly reactive gamma-ketoaldehydes (neuroketals) as products of nueroprostane pathway. J Biol Chem 276:30964-30970.
13. Borgstrom L, Kagedal B, Paulsen O. 1986. Pharmacokinetics of N-acetylcysteine in man. Eur J Pharmacol 31:217-222.
14. Bounous G, Kongshaven P, Gold P. 1988. The immunoenhancing property of dietary whey protein concentrate. Clin Invest Med 11:271-278.
15. Bounous G, Gervais F, Amer V, Batist G, Cold P. 1989. The influence of dietary whey protein on tissue glutathione and the diseases of aging. Clin Invest Med 12:343-349.
16. Bouras C, Giannakopoulos P, Good PF, Hsu A, Hof PR, Perl DP. 1997. A laser microprobe mass analysis of brain aluminum and iron in dementia pugilistica: comparison with Alzheimer's disease. Eur Neurol 38:53-58.
17. Brame CJ, Salomon RG, Morrow JD, Roberts LJ 2nd. 1999. Identification of extremely reactive gamma-ketoaldehydes (isolevuglandins) as products of the isoprostane pathway and characterization of their lysyl protein adducts. J Biol Chem 274:13139-13146.
18. Butterfield DA. 1997. beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Chem Res Toxicol 10:495-506.
19. Butterfield DA, Kanski J. 2001. Brain protein oxidation in agerelated neurodegenerative disorders that are associated with aggregated proteins. Mech Ageing Dev 122:945-962.
20. Butterfield DA, Kanski J. 2002. Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid-peptide 1-42. Peptides 23:1299-1309.
21. Butterfield DA, Lauderback CM. 2002. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: Potential causes and consequences involving amyloid-peptide-associated free radical oxidative stress. Free Radic Biol Med 32:1050-1060.
22. Butterfield DA, Stadtman ER. 1997. Protein oxidation processes in aging brain. Adv Cell Aging Gerontol 2:161-191.
23. Butterfield DA, Drake J, Pocernich C, Castegna A. 2001. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 7:548-554.
24. Butterfield DA, Castegna A, Lauderback CM, Drake J. 2002a. Review: evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contibutes to neuronal death. Neurobiol Aging (in press).
25. Butterfield DA, Castegna A, Drake J, Scapagnini G, Calabrese V. 2002b. Vitamin E and neurodegenerative disorders associated with oxidative stress. Nutr Neurosci 5:229-239.
26. Butterfield DA, Castegna A, Pocernich C, Drake J, Scapagnini G, Calabrese V. 2002c. Nutritional approaches to combat oxidative stress in Alzheimer's disease brain. J Nutr Biochem (in press).
27. Calabrese V, Bates TE, Stella AM. 2000. NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance. Neurochem Res 25:1315-1341.
28. Calingasan N, Uchida K, Gibson GE. 1999. Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J Neurochem 72:751-756.
29. Cao Y, Kennedy R, Klimberg VS. 1999. Glutamine protects against doxorubicin-induced cardiotoxicity. J Surg Res 85:178-182.
30. Coloso RM, Hirschberger LL, Stipanuk MH. 1991. Uptake and metabolism of L-2-oxo-[35S]thiazolidine-4-carboxylate by rat cells is slower than that of L-[35S] cysteine or L-[35S]methionine. J Nutr 121:1341-1348.
31. Connor JR, Menzies SL, Marti SM. 1992. A histochemichal study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res 20:579-587.
32. Cooper AJL. 1997. Glutathione in the brain: disorders of glutathione metabolism. The molecular and genetic basis of neurological disease. Newton, MA: Butterworth-Heinemann. p 1195-1230.
33. Deibel MA, Ehmann WD, Markesbery WR. 1996. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J Neurol Sci 143:137-142.
34. Deneke SM, Susanto I, Vogel KA, Williams CE, Lawrence RA. 1995. Mechanisms of use of extracellular glutathione by lung epithelial cells and pulmonary artery endothelial cells. Am J Respir Cell Mol Biol 12:662-668.
35. Drake J, Kanski J, Varadarajan S, Tsoras M, Butterfield DA. 2002. Elevation of brain glutathione by γ-glutamylcysteine ethyl ester protects against peroxynitrite-induced oxidative stress. J Neurosci Res 68:776-784.
36. Dringen R, Hamprecht B. 1999. N-actlcysteine, but not methionine or 2-oxothiazolidine-4-carboxylate, serves as cysteine donor for the synthesis of glutathione in cultured neurons derived from embryonal rat brain. Neurosci Lett 259:79-82.
37. Dringen R, Hamprecht B, Broer S. 1998. The peptide transporter PepT2 mediates the uptake of the glutathione precursor CysGly in astroglia-rich primary cultures. J Neurochem 71:388-393.
38. Dringen R, Pfeiffer B, Hamprecht B. 1999. Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurosci 19:562-569.
39. Dringen R, Gutterer JM, Gros C, Hirrlinger J. 2001. Aminopeptidase N mediates the utilization of the GSH precursor CysGly by cultured neurons. J Neurosci Res 66:1003-1008.
40. Esterbauer H, Schaur RJ, Zollner H. 1991. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11:81-128.
41. Foresti R, Clark JE, Green CJ, Motterlini R. 1997. Thiol compounds interact with nitric oxide in regulating heme oxegenase-1 induction in endothelial cells. Involvement of superoxide and peroxynitrite anions. J Biol Chem 272:18411-18417.
42. Hammond CL, Lee TK, Ballatori N. 2001. Novel roles for glutathione I gene expression, cell death, and membrane transport of organic solutes. J Hepatol 34:946-954.
43. Harward TR, Coe D, Souba WW, Klingman N, Seeger JM. 1994. Glutamine preserves gut glutathione levels during intestinal ischemia/reperfusion. J Surg Res 56:351-355.
44. Heales SJ, Bolanos JP. 2002. Impairment of brain mitochondrial function by reactive nitrogen species: the role of glutathione in dictating susceptibility. Neurochem Int 40:469-474.
45. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita SP, Wu JF, Carney JM, Butterfield DA. 1995. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 65:2146-2156.
46. Hensley K, Maidt ML, Yu Z, Sang H, Markesbery, WR, Floyd RA. 1998. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 18:8126-8132.
47. Hong BW, Rounds JD, Helton WS, Robinson MK, Wilmore DW. 1992. Glutamine preserves liver glutathione after lethal hepatic injury Ann Surg 215:114-119.
48. Horton ND, Mamiya BM, Kehrer JP. 1997. Relationships between cell density, glutathione and proliferation of A549 human lung adenocarcinoma cells treated with acrolein. Toxicology 122:111-122.
49. Hoshida S, Kuzuya T, Yamashita N, Nishida M, Kitahara S, Hori M, Kamada T, Tada M. 1994. Gamma-glutamylcysteine ethyl ester for myocardial protection in dogs during ischemia and reperfusion. J Am Coll Cardiol 24:1391-1397.
50. Irizarry MC, Hyman BT 2001. Alzheimer disease therapeutics. J Neuropathol Exp Neurol 60:923-928.
51. Jain A, Madsen DC, Auld PA, Frayer WW, Schwartz MK, Meister A, Martensson J. 1995. L-2-oxothiazolidine-4-carboxylate, a cysteine precursor, stimulates growth and normalizes tissue glutathione concentrations in rats fed a sulfur amino acid-deficient diet. J. Nutr 125:851-856.
52. Kalayjian RC, Skowron G, Emgucov RT 1994. A phase I/II trial of intravenous L-2-oxothiazolidine-4-carboxylic acid (procysteine) in asymptomatic HIV-infected subjects. J AIDS 7:369-374.
53. Kamencic H, Junrlink BH. 2001. Glutamine increases glutathione levels in rat astrocytes. Poster presented at Society for Neuroscience Meeting.
54. Katzman R, Saitoh T. 1991. Advances in Alzheimer's disease. FASEB J 5:278-286.
55. Keller JN, Mark RJ, Bruce AJ, Blanc E, Rothstein JD, Uchida K, Waeg G, Mattson MP. 1997a. 4-Hydroxynonenal, an aldehyde product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in syamptosomes. Neuroscience 80:685-696.
56. Keller JN, Pang Z, Geddes JW, Begley JG, Germeyer A, Waeg G, Mattson MP. 1997b. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid β-peptide: role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem 69:273-284.
57. Kennard ML, Feldman H, Yamada T 1996. Serum levels of the iron protein p97 are elevated in Alzheimer's disease. Nat Med 2:1230-1235.
58. Kharazmi A, Nielsen H, Sehiotz PO. 1988. N-acelcysteine inhibits human neutrophil and monocyte chemotaxis and oxidative metabolism. Int J Immunopharmac 10:39-46.
59. Kobayashi H, Kurokawa T, Kitahara S, Nonami T, Harada A, Nakao A, Sugiyama S, Ozawa T, Takagi H. 1992. The effects of gammaglutamylcysteine ethyl ester, a prodrug of glutathione, on ischemia-reperfusion-induced liver injury in rats. Transplantation 54:414-418.
60. Koppal T, Drake J, Yatin S, Jordan B, Varadarajan S, Bettenhausen L, Butterfield DA. 1999a. Peroxynitrite-induced alterations in synaptosomal membrane proteins: insight into oxidative stress in Alzheimer's disease. J Neurochem 72:310-317.
61. Koppal T, Drake J, Butterfield DA. 1999b. In vivo modulation of rodent glutathione and its role in peroxynitrite-induced neocortical synaptosomal membrane protein damage. Biochim Biophys Acta 1453:407-411.
62. Kranich O, Hampricht B, Dringen R. 1996. Different preferences in the utilization of aminoacids for glutathione synthesis in cultured neurons and astogligal cells derived from rat brain. Neurosci Lett 219:211-214.
63. LaFontaine MA, Geddes JW, Banks A, Butterfield DA. 2000a. 3-Nitropropionic acid induced in vivo protein oxidation in striatal and cortical synaptosomes: insights into Huntington's disease. Brain Res 858:356-362.
64. LaFontaine MA, Geddes JW, Banks A, Butterfield DA. 2000b. Effect of exogenous and endogenous andoxidants on 3-nitropionic acid-induced in vivo oxidative stress and striatal lesions: insights into Huntington's disease. J Neurochem 75:1709-1715.
65. Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbexy WR, Butterfield DA. 2001. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J Neurochem 78:413-416.
66. Levy EJ, Anderson ME, Meister A. 1993. Transport of glutathione diethyl ester into human cells. Proc Natl Acad Sci USA 90:9171-9175.
67. Lovell MA, Ehmann WD, Markesbery WR. 1993. Laser microprobe analysis of brain aluminum in Alzheimer's disease. Ann Neurol 33:36-42.
68. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. 1998a. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158:47-52.
69. Lovell MA, Xie C, Markesbery WR. 1998b. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology, 51:1562-1566.
70. Lovell MA, Xie C, Markesbery WR. 2001. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 22:187-94.
71. Mark RJ, Lovell MA, Markesbery, WR, Uchida K, Mattson MP. 1997a. A role for 4-hydroxnonenal, an aldehyde product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid β-peptide. J Neurochem 68:255-264.
72. Mark RJ, Pang Z, Geddes JW, Uchida K, Mattson MP. 1997b. Amyloid β-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci 17:1046-1054.
73. Mark RJ, Fuson KS, May PC. 1999. Characterization of 8-epiprostaglandin F2alpha as a marker of amyloid beta-peptide-induced oxidative damage. J Neurochem 72:1146-1153.
74. Markesbery WR. 1997. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23:134-147.
75. Markesbery WR, Lovell MA. 1998. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19:33-36.
76. Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L. 1996. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol 40:759-766.
77. Meister A, Anderson ME. 1983. Glutathione. Annu Rev Biochem 52:711-760.
78. Meister A, Tate SS, Griffith OW. 1981. Gamma-glutamyl transpeptidase. Meth Enzymol 77:237-253.
79. Micke P, Beeh KM, Schlaak JF, Buhl R. 2001, Oral supplementation with whey proteins increases plasma glutathione levels of HIV-infected patients. Eur J Clin Invest 31:171-178.
80. Milchak LM, Douglas Bricker J. 2002, The effects of glutathione and vitamin E on iron toxicity in isolated rat hepatocytes. Toxicol Lett 126:169-177.
81. Moberly J, Logan J, Borum P. 1998. Elevation of whole-blood glutathione in peritoneal dialysis patients by L-2-oxothiazolidine-4-carboxylate, a cysteine prodrug. J Am Soc Nephrol 9:1093-1099.
82. Montine KS, Olson SJ, Amarnath V, Whetsell Jr, WO, Graham DG, Montine TJ. 1997. Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of apoE4. Am J Pathol 150:437-443.
83. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ 2nd. 1998. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol 44:410-413.
84. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, Bachrach AF, Zackert WE, Roberts LJ, Morrow JD. 1999. Increased CSF F2-isoprostane concentration in probable AD. Neurology 52:562-565.
85. Motterlini R, Foresti R, Bassi R, Calabrese V, Clark JE, Green CJ. 2000. Endothelial heme oxygenase-1 induction by hypoxia. Modulation by inducible nitric-oxide synthase and S-nitrosothiols. J Biol Chem 275:13613-13620.
86. Nishida K, Ohta Y, Ito M, Nagamura Y, Kitahara S, Fujii K, Ishiguro I. 1996. Conversion of gamma-glutamylcysteinylethyl ester to glutathione in rat hepatocytes. Biochim Biophys Acta 1313:47-53.
87. Nishida K, Ohta Y, Ishiguro I, 1998. Preventive effect of gammaglutamylcysteinylethyl ester on carbon tetrachloride-induced hepatic triglyceride accumulation in mice. Toxicol Lett 95:141-146.
88. Nishinaka Y, Kitahara S, Sugiyama S, Yokota M, Saito H, Ozawa T. 1991. The cardioprotective effect of gamma-glutamylcysteine ethyl ester during coronary reperfusion in canine hearts. Br J Pharmacol 104:805-810.
89. Nishiuch Y, Sasaki M, Nakayasu M, Oidawa A. 1976. Cytotoxicity of cysteine in culture media. In Vitro 12:635-638.
90. Ohno Y, Ormstad K, 1985. Formation, toxicity and inactivation of acrolein during biotransformation of cyclophosphamide as studied in fleshly isolated cells from rat liver and kidney. Arch Toxicol 57:99-103.
91. Okamoto T, Mizuta K, Takahashi T, Kishi T, Kitahara S, Komori S, Hashimoto K, Goshima K. 1999. Protective effect of gammaglutamyleysteinylethyl ester on dysfunction of the selenium-deficient rat heart. Biochem Pharmacol 57:955-963.
92. Olivieri G, Baysang G, Meier F, Muller-Spahn F, Stahelin HB, Brockhaus M, Brack C. 2001, N-acetyl-L-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: effects on beta-amyloid secretion and tau phosphorylation. J Neurochem 76:224-233.
93. Olney JW, Ho O, Rhee V. 1971. cytotoxic effect of acid and sulphur containing amino acids on the infant mouse central nervous system. Brain Res 14:61-76.
94. Ozaki M, Ozasa H, Fuchinoue S, Teraoka S, Ota K. 1994, Protective effects of glycine and esterified gamma-glutamyleysteine on isehemia/reoxygenation injury of rat liver. Transplantation 58:753-755.
95. Pileblad E, Magnusson T. 1992. Increase in rat brain glutathione following intracerebroventricular administration of gamma-glutamylcysteine, Biochem Pharmacol 44:895-903.
96. Pocernich CB, La Fontaine M, Butterfield DA. 2000. In-vivo glutathione elevation protects against hydroxyl against hydroxyl free radical-induced protein oxidation in rat brain. Neurochem Int 36:185-191.
97. Pocernich CB, Cardin AL, Racine CL, Lauderback CM, Butterfield DA. 2001. Glutahione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: relevance to brain lipid peroxidation in neurodegenerative disease. Neurochem Int 39:141-149.
98. Poeggeler B, Miravalle L, Zagorsld MG, Wisniewski T, Chyan YJ, Zhang Y, Shao H, Bryant-Thomas T, Vidal B, Frangione B, Ghiso J, Pappolla MA. 2001. Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide. Biochemistry 40:14995-5001.
99. Porta P, Aebi S, Summer K, Lauterburg BH. 1991. L-2-oxothiazolidine-4-carboxylic acid, a cysteine prodrug: pharmacokenetics and effects on thiols in plasma and lymphocytes in human. J Pharmacol Exp Ther 257:331-334.
100. Quijano C, Alvarez B, Gatti RM, Augusto O, Radi R. 1997. Pathways of peroxynitrite oxidation of thiol groups. Biochem J 322:167-173.
101. Rouse K, Nwokedi E, Woodliff JE, Epstein J, Klimberg VS. 1995. Glutamine enhances selectivity of chemotherapy through changes in glutathione metabolism. Ann Surg 221:420-426.
102. Sagara J, Miura K, Bannai S. 1993. Maintenance of neuronal glutathione by glial cells. J Neurochem 61:1672-1676.
103. Sagara J, Makino N, Bannai S. 1996. Glutathione efflux from cultured astrocytes. J Neurochem 66:1876-1881.
104. Sayre LM, Zelasko DA, Harris PLR, Perry, G, Salomon RG, Smith MA. 1997. 4-Hydroxynonenal-derived advance lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68:2092-2097.
105. Selkoe DJ. 2000. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad Sci 924:17-25.
106. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. 1997. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17:2653-2657.
107. Studer R, Baysang G, Brack C. 2001. N-acetyl-L-cystein downregulates beta-amyloid precursor protein gene transcription in human neuroblastoma cells. Biogerontology 2:55-60.
108. Su JH, Deng G, Cotman CW. 1997. Neuronal DNA damage precedes tangle formation and is associated with up regulation of nitrotyrosine in Alzheimer's disease brain. Brain Res 774:193-199.
109. Subramaniam R, Roediger F, Mattson MP, Keller JN, Waeg G, Butterfield DA. 1997. The lipid peroxidation product 4-hydroxy2-trans-nonenal alters conformation of cortical synaptosomal membrane proteins, J Neurochem 69:1161-1169.
110. Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C. 1999. Alterations of 3-nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci Lett 269:52-54.
111. Uchida K, Kanematsu M, Sakai K, Matsuda T, Hattori N, Mizuno Y, Suzuki D, Miyata T, Noguchi N, Nild E, Osawa T. 1998. Proteinbound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci USA 95:4882-4887.
112. Varadarajan S, Yatin S, Aksenova M, Butterfield DA. 2000. Review: Alzheimer's amyloid β-amyloid peptide-associated free radical oxidative stress and neurotoxicity J Struct Biol 130:184-208.
113. Varadarajan S, Kanski J, Aksenova M, Lauderback C, Butterfield DA. 2001. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta(1-42) and A beta(25-35). J Am Chem Soc 123:5625-5631.
114. Welbourne TC. 1979. Ammonia production and glutamine incorporation into glutathione in the functioning rat kidney. Can J Biochem 57:033-237.
115. Williamson JM, Boettcher B, Meister A. 1982. Intracellular cysteine delivery system that protects against toxicity by promoting glutathione synthesis. Proc Natl Acad Sci USA 79:6246-6249.
116. Williamson KS, Prasad Gabbita S, Mou S, West M, Pye QN, Markesbery, WR, Cooney RV, Grammas P, Reimann-Philipp U, Floyd RA, Hensley K. 2002. The nitration product 5-nitrogamma-tocopherol is increased in the Alzheimer brain. Nitric Oxide 6:221-227.
117. Xie C, Lovell MA, Markesbery WR. 1998. Glutathione transferase protects neuronal cultures against four hydroxynonenal toxicity. Free Radic Biol Med 25:979-988.
118. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, Scott CW, Caputo C, Frappier T Smith MA, Perry G, Yen SH, Stern D. 1994. Glycated tau protein in Alzheimer's disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 91:7787-7791.
119. Yatin SM, Varadarajan S, Link CD, Butterfield DA. 1999. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42). Neurobiol Aging 20:325-330.
120. 15N] glutamate. J Neurochem 55:137-145.
121. Zommara M, Toubo H, Sakono M, Imaizumi K. 1998. Prevention of peroxidative stress in rats fed on a low vitamin E-containing diet by supplementing with a fermented bovine milk whey preparation: effect of lactic acid and β-lactoglobulin on the antiperoxidative action. Biosei Biotechnol Biochem 62:710-717.